Department of Laboratory Medicine and Pathology, Virology Division, University of Washington, Seattle, WA, United States.
Department of Laboratory Medicine and Pathology, Virology Division, University of Washington, Seattle, WA, United States; Department of Biomedical Informatics and Medical Education, University of Washington School of Medicine, Seattle, WA, United States.
J Clin Virol. 2020 Oct;131:104570. doi: 10.1016/j.jcv.2020.104570. Epub 2020 Aug 2.
SARS-CoV-2 testing demand has outpaced its supply. Pooling samples for lower risk populations has the potential to accommodate increased demand for SARS-CoV-2 molecular testing.
To evaluate the sensitivity, specificity, and reproducibility of 4-way pooling of SARS-CoV-2 specimens for high-throughput RT-PCR.
Individual samples were pooled 1:4 through automated liquid handling, extracted, and assayed by our emergency use authorized CDC-based RT-PCR laboratory developed test. Positive samples were serially diluted and theoretical and empirical PCR cycle thresholds were evaluated. Thirty-two distinct positive samples were pooled into negative specimens and individual CTs were compared to pooled CTs. Low positive samples were repeated for reproducibility and 32 four-way pools of negative specimens were assayed to determine specificity.
Four-way pooling was associated with a loss of sensitivity of 1.7 and 2.0 CTs for our N1 and N2 targets, respectively. Pooling correctly identified SARS-CoV-2 in 94 % (n = 30/32) of samples tested. The two low positive specimens (neat CT > 35) not detected by pooling were individually repeated and detected 75 % (n=6/8) and 37.5 % (n = 3/8) of the time, respectively. All specimens individually determined negative were also negative by pooling.
We report that 1:4 pooling of samples is specific and associated with an expected 2 CT loss in analytical sensitivity. Instead of running each sample individually, pooling of four samples will allow for a greater throughput and conserve scarce reagents.
SARS-CoV-2 的检测需求已经超过了供应。对低风险人群进行样本合并,有可能满足对 SARS-CoV-2 分子检测需求的增加。
评估高通量 RT-PCR 中 SARS-CoV-2 标本 4 向合并的灵敏度、特异性和可重复性。
通过自动化液体处理将单个样本以 1:4 的比例合并,提取并由我们获得紧急使用授权的基于 CDC 的 RT-PCR 实验室开发的测试进行检测。对阳性样本进行连续稀释,并评估理论和经验 PCR 循环阈值。将 32 个不同的阳性样本合并到阴性样本中,并将个体 CT 与合并 CT 进行比较。对低阳性样本进行重复性检测,对 32 个阴性样本进行 4 向合并检测,以确定特异性。
四向合并分别导致我们的 N1 和 N2 靶标灵敏度损失 1.7 和 2.0 CT。合并正确识别了 94%(n=30/32)的测试样本中的 SARS-CoV-2。2 个未被合并检测到的低阳性样本(未稀释 CT > 35)单独重复检测时,分别有 75%(n=6/8)和 37.5%(n=3/8)的时间被检测到。所有单独确定为阴性的样本通过合并也为阴性。
我们报告,样本 1:4 合并具有特异性,并与分析灵敏度预计的 2 CT 损失相关。合并 4 个样本而不是逐个运行每个样本,将允许更大的通量并节省稀缺的试剂。